Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

Pharmacogenetics - 1 Aug 2004

Kivistö Kari T, Niemi Mikko, Schaeffeler Elke, Pitkälä Kaisu, Tilvis Reijo, Fromm Martin F, Schwab Matthias, Eichelbaum Michel, Strandberg Timo

Abstract excerpt

Individuals expressing the polymorphic CYP3A5 enzyme might show a more than average efficiency in the metabolism of lovastatin, simvastatin and atorvastatin. We studied whether the expression of CYP3A5 is associated with an impaired lipid-lowering response to statins in 69 Caucasian patients. Lovastatin, simvastatin and atorvastatin were significantly less effective in CYP3A5 expressors than in non-expressors....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Lovastatin

Share to Pyrroles

Share to Simvastatin

Source

Identifiers

PMID: 15284534
DOI: 10.1097/01.fpc.0000114762.78957.a5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid-lowering response to statins is affected by CYP3A5 polymorphism.PMID 15284534Read ↗

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.Semantic proximity Read ↗

Statin regulation of CYP3A4 and CYP3A5 expression.Semantic proximity Read ↗

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Semantic proximity Read ↗

CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin.Semantic proximity Read ↗

Impact of apolipoprotein A5 variants on statin treatment efficacy.Semantic proximity Read ↗

Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.Semantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Semantic proximity Read ↗

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.Semantic proximity Read ↗

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.Semantic proximity Read ↗

Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.